In non-small-cell-lung cancer, MET amplification is thought to be responsible for resistance to targeted drugs in EGFR-mutation-positive patients, which results in malignant biological behavior of tumors, such as invasion, metastasis, escape from apoptosis (Coleman et al., 2021). This evidence concerns the gene EGFR and non-small cell lung carcinoma.